Asterias Biotherapeutics, Inc.
CIK 0001572552
Revenue (TTM)
$2.23M
Q3 Sep 2018
Net Income (TTM)
−$20.56M
+20.1% YoY
Q3 Sep 2018
EPS Diluted (TTM)
—
Q3 Sep 2018
Gross Margin
95.7%
Q3 Sep 2018
Operating Margin
-1,036.3%
Q3 Sep 2018
Net Margin
-922.3%
Q3 Sep 2018
Free Cash Flow (TTM)
−$12.58M
Q3 Sep 2018
Cash
$6.42M
Q3 Sep 2018
Total Debt
—
Q3 Sep 2018
Shares Outstanding
30.9M sh
Q3 Sep 2018
Revenue & Net Income
Cash Flow
Revenue Growth (YoY)
No data available for this metric.